ONC News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

ON

Mkt Cap

$41.76B

Volume

368.74K

Next Earnings

November 5th

Loading chart

ON

ONCBeOne Medicines Ltd. American Depositary Shares

ONC

Pay with—

Available Balance0.00

ON

Mkt Cap

$42.32B

Volume

368.74K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

All You Need to Know About BeOne Medicines Ltd. - Sponsored ADR (ONC) Rating Upgrade to Strong BuyBeOne Medicines Ltd. - Sponsored ADR (ONC) has been upgraded to a Zacks Rank #1 (Strong Buy) rating, primarily driven by upward trends in earnings estimates. Over the past three months, the Zacks Consensus Estimate for the company has increased 53.4%. The upgrade positions the stock in the top 5% of Zacks-covered stocks, suggesting potential for near-term price appreciation based on improving earnings outlook.Zacks Investment Research · Oct 15, 2026

JAZZ Rises on Updated OS Results From Gastric Cancer StudyJazz Pharmaceuticals announced second interim results from the HERIZON-GEA-01 study showing statistically significant overall survival improvements for Ziihera plus chemotherapy versus standard of care trastuzumab plus chemotherapy in HER2-positive gastroesophageal adenocarcinoma. The three-drug regimen of Ziihera plus Tevimbra and chemotherapy also demonstrated improved OS hazard ratios with longer follow-up. These results support the recent FDA label expansion of Ziihera for first-line treatment in this indication, significantly expanding its commercial opportunity.Zacks Investment Research · Sep 1, 2026

Zymeworks Announces Participation in Upcoming Investor ConferencesZymeworks Inc. announced its participation in three upcoming investor conferences: the 2026 Stifel Virtual Targeted Oncology Forum (May 20), TD Cowen 7th Annual Oncology Innovation Summit (May 27), and 2026 Jefferies Global Healthcare Conference (June 3). The company will engage in fireside chats and one-on-one meetings to discuss its portfolio of licensed healthcare assets and pipeline of novel biotherapeutics.GlobeNewswire Inc. · May 13, 2026

Molecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of DirectorsMolecular Partners AG announced its Annual General Meeting scheduled for April 14, 2026, and nominated Clare Fisher, SVP of Global Business Development and M&A at BeOne Medicines, to join its Board of Directors. Current board member Steven H. Holtzman will not seek re-election after 12 years of service. Fisher brings over two decades of healthcare leadership experience in business development, M&A, and strategy from roles at companies including Takeda, Cubist Pharmaceuticals, and Blueprint Medicines.GlobeNewswire Inc. · Mar 23, 2026

Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026Zymeworks Inc. announced it will report its fourth quarter and full year 2025 financial results on March 2, 2026, followed by a conference call at 8:30 am ET. The biotechnology company is managing a portfolio of licensed healthcare assets and developing multifunctional biotherapeutics, with key products including Ziihera and partnerships with BeOne Medicines and Jazz Pharmaceuticals for commercialization rights.GlobeNewswire Inc. · Feb 12, 2026

FDA Accepts Summit's Lung Cancer Drug Application, Review UnderwayThe FDA has accepted Summit Therapeutics' Biologics License Application for ivonescimab in combination with chemotherapy for EGFR-mutated non-small cell lung cancer patients. The drug will undergo complete review with a PDUFA goal action date of November 14, 2026. Phase 3 trial data showed ivonescimab demonstrated improved overall survival compared to chemotherapy alone, and the company is expanding its clinical development program with additional Phase 3 studies.Benzinga · Jan 29, 2026

Zymeworks Announces Participation in Upcoming Investor ConferencesZymeworks Inc. announced that its management will participate in multiple investor conferences in February and March 2026, including Citi's Virtual Oncology Leadership Summit, TD Cowen Health Care Conference, Leerink Global Healthcare Conference, and Citizens Life Science Conference. The company continues to advance its portfolio of licensed healthcare assets and biotherapeutics pipeline.GlobeNewswire Inc. · Jan 27, 2026

Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival BenefitZymeworks announced positive Phase 3 HERIZON-GEA-01 results for Ziihera (zanidatamab-hrii) in combination with chemotherapy, with or without tislelizumab, for first-line treatment of HER2-positive gastroesophageal adenocarcinoma. The trial demonstrated statistically significant improvements in progression-free survival (approximately 35% risk reduction) and overall survival (26.4 months median, representing a 7+ month improvement over trastuzumab). Zymeworks is eligible to receive up to $440 million in milestone payments from regulatory approvals across major markets.GlobeNewswire Inc. · Jan 6, 2026

AMGEN ANNOUNCES 2026 FIRST QUARTER DIVIDENDAmgen's Board of Directors declared a $2.52 per share dividend for Q1 2026, to be paid on March 6, 2026, to stockholders of record as of February 13, 2026.Benzinga · Dec 9, 2025

BeOne Medicines Announced Sonrotoclax In Combination With BRUKINSA Demonstrated Rapid MRD Negativity In Treatment-naive CLL, Regardless Of High-risk FeaturesBeOne Medicines presented new data on sonrotoclax, a BCL2 inhibitor, showing promising clinical benefits in B-cell malignancies, including meaningful responses in mantle cell lymphoma and chronic lymphocytic leukemia.Benzinga · Dec 7, 2025

to start trading

ON

ONCBeOne Medicines Ltd. American Depositary Shares

ONC

Pay with—

Available Balance0.00

Your PositionYou don't own any ONC yet.

Related Tickers

Earnings